H. Kakiya et al. / Tetrahedron 56 (2000) 2131±2137
2135
General procedure for the reaction of gem-dibromo-
cyclopropane with trialkylmanganate followed by
addition of electrophile
0.88H), 0.31±0.40 (m, 1H), 0.43±0.54 (m, 1H), 0.81±0.99
(m, 6H), 1.14±1.42 (m, 20H), 1.76 (dd, J14.7, 6.6 Hz,
0.12H), 1.90 (dd, J14.7, 6.6 Hz, 0.88H), 2.00±2.16 (m,
1H), 4.92±5.06 (m, 2H), 5.68±5.88 (m, 1H); 13C NMR
(CDCl3) d 13.91, 17.68, 18.01, 22.55, 23.05, 23.77,
24.11, 26.65, 29.19, 29.37, 29.48, 29.68, 30.06, 30.71,
31.83, 35.24, 37.80, 115.33, 115.49, 137.18, 137.80.
Found: C, 86.04; H, 13.76%. Calcd for C18H34: C, 86.32;
H, 13.68%.
Preparation of 1-butyl-2-hexyl-1-iodocyclopropane is
representative (Entry 6, Table 1). A solution of 1a (0.28 g,
1.0 mmol) in THF (2 ml) was added to a solution of
tributylmanganate generated from MnCl2 (151 mg,
1.2 mmol) and butylmagnesium bromide (3.6 mmol). The
resulting mixture was stirred at 08C for 1 h and then at 258C
for 20 min. The mixture was cooled to 2788C and iodine
(0.46 g, 3.6 mmol) was added. The whole was warmed to
room temperature over 1 h and stirred for another 30 min.
The mixture was poured into aq. Na2S2O3 and extracted with
hexane (3£20 ml). Puri®cation by silica-gel column
chromatography gave a mixture of cis- and trans-1-butyl-
2-hexyl-1-iodocyclopropane (cis/trans72/28): Bp 130±
1408C (bath temp, 0.5 Torr); IR (neat) 3058, 2954, 2924,
2852, 1466, 1379, 1294, 1261, 1211, 1164, 1116, 1031, 942,
7-Allyl-7-butylnorcarane (2/397/3). IR (neat) 3072,
1
2924, 2854, 1639, 1467, 1449, 1377, 991, 909 cm21; H
NMR (CDCl3) d 0.56±0.66 (m, 2H), 0.86 (t, J6.9 Hz,
2.91H), 0.91 (t, J7.2 Hz, 0.09H), 1.06±1.46 (m, 12H),
1.79±1.93 (m, 2.06H), 2.09 (d, J6.6 Hz, 1.94 H), 4.97
(d, J10.2 Hz, 0.03H), 4.98 (d, J17.1 Hz, 0.03H), 5.03
(d, J10.2 Hz, 0.97H), 5.08 (d, J17.1 Hz, 0.97H), 5.83
(ddt, J17.1, 10.2, 6.6 Hz, 1H); 13C NMR (CDCl3) d
14.02, 18.54, 19.11, 22.15, 22.84, 24.46, 28.26, 30.85,
38.95, 115.36, 137.32.
914, 800, 724 cm21 1H NMR (CDCl3) d 20.05±0.10
;
(m, 0.72H), 0.32 (t, J6.3 Hz, 0.28H), 0.68 (t, J6.0 Hz,
0.72H), 0.80±0.98 (m, 6H), 1.02±1.75 (m, 17.28H);
13C NMR (CDCl3) d 13.98, 14.01, 21.81, 22.00, 22.51,
22.56, 22.80, 23.67, 24.02, 24.67, 28.63, 28.70, 29.01,
29.17, 30.17, 31.68, 31.77, 32.50, 36.95, 39.15, 46.00.
Found: C, 50.79; H, 8.40%. Calcd for C13H25I: C, 50.66;
H, 8.17%.
9-Benzoyl-9-butylbicyclo[6.1.0]nonane (2/384/16). IR
(neat) 3056, 3022, 2954, 2920, 2852, 1672, 1598, 1581,
1467, 1449, 1349, 1280, 1250, 1210, 1196, 1174, 1073,
1053, 1020, 976, 960, 935, 806, 782, 741, 715, 691 cm21
;
1H NMR (CDCl3) d 0.76 (t, J6.9 Hz, 2.52H), 0.86 (t,
J7.2 Hz, 0.48H), 0.90±1.08 (m, 4H), 1.10±1.42 (m, 8H),
1.48±1.69 (m, 6H), 1.97±2.06 (m, 2H), 7.39±7.55 (m, 3H),
7.94±8.00 (m, 2H); 13C NMR (CDCl3) major product d
13.76, 22.33, 24.43, 26.22, 28.47, 29.55, 29.65, 35.87,
39.95, 128.37, 129.57, 132.55, 137.32, 200.61. Found:
C, 84.28; H, 10.01%. Calcd for C20H28O: C, 84.45; H,
9.92%.
Physical data for 1-butyl-1-methyl-2-hexylcyclopropane
and 1-benzoyl-1-butyl-2-hexylcyclopropane were identical
with those reported in literature.3,13
1-Allyl-1-butyl-2-hexylcyclopropane (2/389/11). IR
(neat) 3072, 3050, 2954, 2920, 2852, 1640, 1467, 1459,
1
1415, 1379, 1020, 993, 909, 723 cm21; H NMR (CDCl3)
1-Allyl-1-butyl-2-phenylcyclopropane (2/392/8). IR
(neat) 3058, 3022, 2992, 2952, 2922, 2854, 1639, 1605,
1498, 1457, 1440, 1416, 1378, 1085, 1070, 1028, 996,
d 20.14 (dd, J5.1, 4.5 Hz, 0.11H), 20.09 (dd, J5.4,
4.5 Hz, 0.89H), 0.30±0.39 (m, 1H), 0.43±0.55 (m, 1H),
0.80±0.90 (m, 6H), 1.11±1.44 (m, 16H), 1.76 (dd,
J15.0, 6.6 Hz, 0.11H), 1.92 (dd, J15.0, 6.6 Hz, 0.89H),
2.01±2.16 (m, 1H), 4.93±5.02 (m, 0.22H), 4.98 (d,
J10.2 Hz, 0.89H), 5.02 (d, J17.1 Hz, 0.89H), 5.69±
5.83 (m, 0.11H), 5.81 (ddt, J17.1, 10.2, 6.9 Hz, 0.89H);
13C NMR (CDCl3) d 14.00, 14.06, 18.00, 22.59, 22.86,
22.98, 24.06, 28.50, 29.22, 29.38, 30.07, 31.84, 35.16,
37.44, 115.34, 115.45, 137.75. Found: C, 86.03; H,
13.70%. Calcd for C16H30: C, 86.41; H, 13.59%.
1
910, 775, 728, 696 cm21; H NMR (CDCl3) d 0.69±0.80
(m, 1.24 H), 0.81±0.87 (m, 0.08H), 0.87±0.96 (m, 3.68H),
1.10±1.66 (m, 6.92H), 1.87±1.99 (m, 2H), 2.34 (dd,
J14.1, 7.5 Hz, 0.08H), 4.89 (d, J17.4 Hz, 0.92H), 4.91
(d, J10.2 Hz, 0.92H), 5.07 (d, J9.9 Hz, 0.08H), 5.08 (d,
J16.8 Hz, 0.08H), 5.67 (ddt, J17.4, 10.2, 6.9 Hz, 0.92H),
5.91 (ddt, J16.8, 9.9, 7.2 Hz, 0.08H), 7.12±7.26 (m, 3H),
7.27±7.35 (m, 2H); 13C NMR (CDCl3) d 13.87, 14.01,
16.06, 16.37, 22.67, 22.87, 26.67, 28.40, 28.50, 28.69,
28.85, 30.10, 35.18, 37.18, 41.70, 115.61, 116.21, 125.57,
125.68, 127.86, 127.96, 129.09, 136.58, 136.92, 139.79.
Found: C, 89.59; H, 10.62%. Calcd for C16H22: C, 89.66;
H, 10.34%.
1-Butyl-2-hexyl-1-vinylcyclopropane (2/399/1). IR
(neat) 3080, 3058, 2954, 2920, 2852, 1634, 1460, 1378,
1
1261, 1026, 993, 908, 894, 723 cm21; H NMR (CDCl3) d
0.33±0.40 (m, 1H), 0.52±0.58 (m, 1H), 0.62±0.75 (m, 1H),
0.86 (t, J6.9 Hz, 6H), 1.14±1.48 (m, 16H), 4.93
(dd, J17.1, 1.8 Hz, 1H), 5.01 (dd, J10.5, 1.8 Hz, 1H),
5.69 (dd, J17.1, 10.5 Hz, 1H); 13C NMR (CDCl3) d
14.01, 18.15, 22.58, 22.90, 26.54, 27.43, 29.03, 29.10,
29.13, 29.75, 31.81, 37.99, 113.32, 140.33. Found:
C, 86.21; H, 13.54%. Calcd for C15H28: C, 86.46; H,
13.54%.
1-Allyl-1-butyl-2-[(phenylmethoxy)methyl]cyclopropane
(2/388/12). IR (neat) 3060, 3026, 2988, 2952, 2922, 2852,
1640, 1497, 1455, 1415, 1380, 1363, 1204, 1165, 1093,
1
1076, 1028, 995, 910, 733, 696 cm21; H NMR (CDCl3) d
0.13 (dd, J5.1, 5.1 Hz, 0.12H), 0.18 (dd, J5.1, 5.1 Hz,
0.88H), 0.50±0.59 (m, 1H), 0.87 (t, J6.9 Hz, 3H),
0.92±1.03 (m, 1H), 1.15±1.39 (m, 6H), 1.98±2.16
(m, 2H), 3.41±3.60 (m, 2H), 4.51 (d, J12.0 Hz, 1H),
4.55 (d, J12.0 Hz, 1H), 4.98±5.09 (m, 2H), 5.74±5.93
(m, 1H), 7.27±7.37 (m, 5H); 13C NMR (CDCl3) major
product d 13.95, 16.43, 22.75, 23.17, 23.53, 28.33,
35.40, 37.05, 70.74, 72.59, 115.67, 127.57, 127.78,
1-Allyl-1,2-dihexylcyclopropane (2/388/12). IR (neat)
3072, 3050, 2954, 2920, 2850, 1640, 1460, 1415, 1379,
1
1018, 993, 909, 721 cm21; H NMR (CDCl3) d 20.14
(dd, J5.4, 5.4 Hz, 0.12H), 20.09 (dd, J5.4, 5.4 Hz,